Clinical data | |
---|---|
Trade names | Miltown, Equanil, Meprospan, Amepromat, Quivet, Zirponand, and many others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682077 |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | Hepatic |
Elimination half-life | 10 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.306 |
Chemical and physical data | |
Formula | C9H18N2O4 |
Molar mass | 218.253 g·mol−1 |
3D model (JSmol) | |
Density | 1.229 g/cm3 |
Melting point | 105 to 106 °C (221 to 223 °F) |
Boiling point | 200 °C (392 °F) to 210 °C (410 °F) |
| |
| |
(verify) |
Meprobamate—marketed as Miltown by Wallace Laboratories and Equanil by Wyeth, among others—is a carbamate derivative used as an anxiolytic drug. It was the best-selling minor tranquilizer for a time, but has largely been replaced by the benzodiazepines due to their wider therapeutic index (lower risk of toxicity at therapeutically prescribed doses) and lower incidence of serious side effects.